Abstract: Medical devices as wells as methods for making and using medical devices are disclosed. An example medical device may include a left atrial appendage device. The occlusive medical device includes an expandable frame configured to shift between a first configuration and an expanded configuration and a fabric disposed along at least a portion of the expandable frame. A drug eluting coating is disposed on the fabric, the drug eluting coating including a pharmaceutically active component dispersed within a polymeric carrier.

Abstract: A medical device may be coated with a therapeutic composition that includes a direct oral anticoagulant. An illustrative drug coating composition may comprise an excipient including polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), or poly(vinylidene fluoride)-co-hexafluoropropylene (PVDF-HFP) and a direct oral anticoagulant (DOAC). The illustrative drug coating may be applied to an outer surface of a medical device.

Abstract: Aqueous liquid embolic compositions, for example formed from amino acids, as well as method for making and using aqueous liquid embolic compositions are disclosed. An example aqueous liquid embolic composition may include a di-block or tri-block copolymer including a charged block and a hydrophobic block. The aqueous liquid embolic composition may also include templating agent.

Abstract: Aqueous liquid embolic compositions as well as method for making and using aqueous liquid embolic compositions are disclosed. An example aqueous liquid embolic composition may include a di-block or tri-block copolymer including a hydrophobic monomer block and a charged (polycationic or polyanionic) block. The charged (polycationic or polyanionic) block may include one or more anions. The aqueous liquid embolic composition may also include templating agent.

Abstract: The present disclosure pertains to biodegradable polymeric microspheres that comprise a biodegradable polymer and an immunotherapeutic agent selected from an inhibitor of poly ADP ribose polymerase enzyme (PARP inhibitor) and/or a Toll-like receptor (TLR) agonist wherein (a) 50% of a total amount of the immunotherapeutic agent in the biodegradable polymeric microspheres is released from the biodegradable polymeric microspheres into a 37° C. solution of PBS Tween 20 (0.05%) at a point in time ranging from 3 days and 14 days; (b) between 1 mg and 100 mg of immunotherapeutic agent per 1 g dry weight of microspheres is released from the biodegradable polymeric microspheres into a 37° C. solution of PBS Tween 20 (0.05%) at a point in time ranging from 3 days and 14 days; or (c) both (a) and (b). Other aspects of the present disclosure pertain to methods of using such microparticles and kits that contain such microparticles.

Abstract: A device for permanent placement across an atrial appendage ostium in a patient includes a support structure having a contracted delivery configuration and an expanded deployed configuration defining a radially enlarged portion to permanently engage an interior wall of the atrial appendage, a membrane attached to the support structure and configured to extend across the ostium of the atrial appendage when the support structure is in the expanded deployed configuration, and a polymer coating disposed on at least one of the support structure and the membrane, the polymer coating including a direct oral anticoagulant (DOAC) dispersed in a polymer.

Abstract: The present disclosure relates generally to devices, systems, and methods for coil embolization, and, more particularly, to use and methods of forming coated coils. In an aspect, an embolic system may include a coil having a proximal end, a distal end, and a length therebetween slidingly disposed within a sheath. A coating may be disposed about the coil. A delivery filament may be configured to be slidingly disposed within the sheath proximal of the coil such that the coil can be ejected from the distal end of the sheath into the working lumen of a microcatheter. The coating may be configured to substantially fracture as the coil transitions from being substantially aligned with a longitudinal axis of the microcatheter to substantially misaligned with the longitudinal axis of the microcatheter upon being ejected from the microcatheter. The coating may be configured to plasticize after being ejected into an aqueous environment.

Abstract: Medical devices as wells as methods for making and using medical devices are disclosed. An example medical device may include a left atrial appendage device. The left atrial appendage device may include an expandable frame configured to shift between a first configuration and an expanded configuration. A fabric mesh may be disposed along at least a portion of the expandable frame. An anti-thrombogenic coating may be disposed along the fabric mesh.

Abstract: A device for permanent placement across an atrial appendage ostium in a patient includes a support structure having a contracted delivery configuration and an expanded deployed configuration defining a radially enlarged portion to permanently engage an interior wall of the atrial appendage, a membrane attached to the support structure and configured to extend across the ostium of the atrial appendage when the support structure is in the expanded deployed configuration, and a polymer coating disposed on at least one of the support structure and the membrane, the polymer coating including a direct oral anticoagulant (DOAC) dispersed in a polymer.

Abstract: Medical devices as wells as methods for making and using medical devices are disclosed. An example medical device may include a left atrial appendage device. The left atrial appendage device may include an expandable frame configured to shift between a first configuration and an expanded configuration. A fabric mesh may be disposed along at least a portion of the expandable frame. An anti-thrombogenic coating may be disposed along the fabric mesh.

Abstract: The present disclosure relates generally to devices, systems, and methods for coil embolization, and, more particularly, to use and methods of forming coated coils. In an aspect, an embolic system may include a coil having a proximal end, a distal end, and a length therebetween slidingly disposed within a sheath. A coating may be disposed about the coil. A delivery filament may be configured to be slidingly disposed within the sheath proximal of the coil such that the coil can be ejected from the distal end of the sheath into the working lumen of a microcatheter. The coating may be configured to substantially fracture as the coil transitions from being substantially aligned with a longitudinal axis of the microcatheter to substantially misaligned with the longitudinal axis of the microcatheter upon being ejected from the microcatheter. The coating may be configured to plasticize after being ejected into an aqueous environment.

Abstract: In accordance with one aspect, embolic particles are provided which comprise sub-particles that comprise a therapeutic agent of low solubility dispersed in a matrix that comprises a biodegradable polymer. Other aspects pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions. Still other aspects pertain to methods of making such particles.

Abstract: Medical devices as wells as methods for making and using medical devices are disclosed. An example medical device may include a left atrial appendage device. The left atrial appendage device may include an expandable frame configured to shift between a first configuration and an expanded configuration. A fabric mesh may be disposed along at least a portion of the expandable frame. An anti-thrombogenic coating may be disposed along the fabric mesh.

Abstract: In accordance with one aspect, embolic particles are provided which comprise sub-particles that comprise a therapeutic agent of low solubility dispersed in a matrix that comprises a biodegradable polymer. Other aspects pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions. Still other aspects pertain to methods of making such particles.

Abstract: Medical devices and methods for forming the medical devices are disclosed in the present application. In one illustrative example an occlusion balloon comprises an outer balloon member, and an inner balloon member having an inner wall and an outer wall and extending through at least a portion of the outer balloon member. In at least some examples, when forces acting on the inner wall of the inner balloon member equal forces acting on the outer wall of the inner balloon member, the inner balloon member defines a lumen.

Abstract: Systems and methods for performing transcatheter coronary artery bypass grafting procedures are provided. The methods generally involve passing the graft from the aorta to the coronary artery through the pericardial space. The systems include poke-out wires, a coring device, and devices for forming anastomoses at the proximal and distal ends of a vascular graft.

Abstract: Polymer microspheres for embolizing blood vessels and optionally delivering therapeutic agents are provided. The microspheres include PLGA 50:50 and/or Ptx, and are generally formed by emulsion means.

Abstract: In accordance with one aspect, embolic particles are provided which comprise sub-particles that comprise a therapeutic agent of low solubility dispersed in a matrix that comprises a biodegradable polymer. Other aspects pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions. Still other aspects pertain to methods of making such particles.

Abstract: A system and method for treating atherosclerotic plaque. The system includes a first catheter including an expandable balloon and a second catheter including a lumen in fluid communication with a distal hole. The method includes inserting the first catheter into a body lumen adjacent to a plaque formation, and deploying a balloon from the first catheter adjacent to the plaque formation. In addition, the method includes inserting the second catheter adjacent to the first catheter, and routing the distal end portion of second catheter along at least a portion of the deployed balloon of the first catheter. Further, the method includes routing at least a portion of the second catheter into a subintimal space adjacent to the atherosclerotic plaque. Furthermore, the method includes injecting a therapeutic agent into the subintimal space adjacent to the atherosclerotic plaque.

Abstract: In embodiments, medical devices, such balloon catheters or stents, can deliver a therapeutic agent to body tissue of a patient. The medical device a therapeutic coating comprising a polydopamine coated therapeutic agent disposed on a surface of the expandable medical device. In some instances, the therapeutic agent may comprise everolimus.